Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by alleyesonmeon Oct 29, 2021 5:22pm
197 Views
Post# 34066247

International growth.

International growth.International growth potential is where it's at....regulatory hurdles and expenses will pay off and I think we are in for a good surprise come q3..cdn market is an afterthought for me...I have to say the writedowns really piss me off...they need to focus on the top 10 sku's and the rest just stop making already...infused sunscreens is just stupid...now with the balance sheet strong thanks to dilution the upside is compelling at these prices...looking forward to q3....trials are very significant and doctors will be happy to prescribe cbd which is very safe in comparison to all other medications..very bullish and loaded more today at .255 ,happy to hold...
<< Previous
Bullboard Posts
Next >>